Cargando…
Critical Care Management for Novel 2019 SARS-CoV-2 and HCoV-NL63 Coinfection in a Young Immunocompromised Patient: A Chicago Experience
BACKGROUND: SARS-CoV-2 is a newly emerged virus that has spread rapidly, exhibiting tremendous morbidity and mortality. Some potential pharmaceutical targets have been identified but are still lacking proper validation. Case Presentation. We describe the case of a young, immunosuppressed and critica...
Autores principales: | Sanchez-Nadales, Alejandro, Treminio-Quezada, Miguel, Abad, Hasan, Navarro-Motta, Jessica, Contreras-Chavez, Pamela, Kachru, Anil, Chu, Chae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415109/ https://www.ncbi.nlm.nih.gov/pubmed/32802523 http://dx.doi.org/10.1155/2020/8877641 |
Ejemplares similares
-
Seroconversion to HCoV-NL63 in Rhesus Macaques
por: Dijkman, Ronald, et al.
Publicado: (2009) -
Understanding Human Coronavirus HCoV-NL63
por: Abdul-Rasool, Sahar, et al.
Publicado: (2010) -
Novel polymeric inhibitors of HCoV-NL63
por: Milewska, Aleksandra, et al.
Publicado: (2013) -
Human Coronaviruses HCoV-NL63 and HCoV-HKU1 in Hospitalized Children with Acute Respiratory Infections in Beijing, China
por: Cui, Li-Jin, et al.
Publicado: (2011) -
Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2012)